Pfizer's Axitinib Disappoints As RCC Adjuvant Therapy
Executive Summary
An interim analysis has recommended stopping the Phase III ATLAS study because axitinib was failing to show it extended disease-free survival when used as adjuvant therapy in earlier-stage renal cell carcinoma patients. However, combination studies of axitinib with immuno-oncology agents will continue.
You may also be interested in...
Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer
SFJ Pharmaceuticals has taken on the late-stage clinical development of Merck KGaA's previously stalled MAb abituzumab, sharing the financial risk and evaluating patients with left-sided colorectal cancer.
Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections
Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.